Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)

Introduction: Evaluation of health-related quality-of-life (HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR) mutation-positive/negative subgroups in IPASS. Methods: HRQoL was assessed using...

Saved in:

書目詳細資料
Main Authors:	Thongprasert S., Duffield E., Saijo N., Wu Y.-L., Yang J.C.-H., Chu D.-T., Liao M., Chen Y.-M., Kuo H.-P., Negoro S., Lam K.C., Armour A., Magill P., Fukuoka M.
格式:	Article
語言:	English
出版:	2014
在線閱讀:	http://www.scopus.com/inward/record.url?eid=2-s2.0-80054882063&partnerID=40&md5=a3b134d1b53530e6aaf637e86637e5cf http://www.ncbi.nlm.nih.gov/pubmed/22011650 http://cmuir.cmu.ac.th/handle/6653943832/2978
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS)
由: Sumitra Thongprasert, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
由: Tony S. Mok, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Wu Y., et al.
出版: (2017)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC
由: Yi Long Wu, et al.
出版: (2018)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Fukuoka M., et al.
出版: (2017)

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS)
由: Masahiro Fukuoka, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Wu Y.-L., et al.
出版: (2014)

Paclitaxel and Carboplatin in Combination in the Treatment of Advanced Non-small-cell Lung Cancer (NSCLC) : A Preliminary Study
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study
由: Yi Long Wu, et al.
出版: (2018)

Paclitaxel and carboplatin plus megestrol acetate in the treatment of advanced non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Kietpeerakool C., et al.
出版: (2014)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
由: Charoentum C., et al.
出版: (2014)

Phase II study of 24-hour infusion of paclitaxel (Intaxel) with carboplatin in advanced non-small cell lung cancer.
由: Chaiyut Charoentum, et al.
出版: (2018)

Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
由: Laksmi Wulandari, -, et al.
出版: (2022)

Remission of recurrent cervical cancer with paclitaxel and carboplatin: A case report and review of literature
由: W. Termrungruanglert, et al.
出版: (2018)

Lung cancer response to gefitinib, then erlotinib, then gefitinib again
由: Wong, A.S., et al.
出版: (2014)

Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer
由: Kietpeerakool C., et al.
出版: (2014)

Symptom Clusters in Thai Gynecological Oncology Patients Receiving the First Cycle of Carboplatin and Paclitaxel
由: Bualuang Sumdaengrit, et al.
出版: (2022)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Thongprasert S., et al.
出版: (2014)

Cost-effectiveness analysis of cisplatin plus etoposide and carboplatin plus paclitaxel in a phase III randomized trial for non-small cell lung cancer
由: Sumitra Thongprasert, et al.
出版: (2018)

The Comparison of Neutropenia and Peripheral Neuropathy Condition as an Impact of 3-hours and 24-hour Paclitaxel Infusion of Paclitaxel-Carboplatin Chemotherapy on Ovarian Cancer Patients
由: Primandono Perbowo, -, et al.
出版: (2019)

Benefit of electrocardiography during front-line combination paclitaxel and carboplatin chemotherapy for epithelial ovarian cancer
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
由: Reungwetwattana T.
出版: (2023)

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
由: Tan, Eng-Huat, et al.
出版: (2022)

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
由: Ratanatharathorn V., et al.
出版: (2014)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin.
由: Sirichaisutdhikorn D., et al.
出版: (2014)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Sirichaisutdhikorn D., et al.
出版: (2014)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Chumnan Kietpeerakool, et al.
出版: (2018)

Survival and prognostic factors of patients with primary fallopian tube cancer receiving adjuvant paclitaxel and carboplatin chemotherapy
由: Kietpeerakool C., et al.
出版: (2014)

Effects of paclitaxel and carboplatin on quality of life and survival in patients with advanced non-small-cell lung cancer
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Daranee Sirichaisutdhikorn, et al.
出版: (2018)

Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin
由: Daranee Sirichaisutdhikorn, et al.
出版: (2018)

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer
由: Vorachai Ratanatharathorn, et al.
出版: (2018)

Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?
由: Lee, Matilda X, et al.
出版: (2021)